On June 8, 2022 EpiAxis Therapeutics has reported the results of its pioneering clinical trial EPI-PRIMED, the first time that an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer (Press release, EpiAxis Therapeutics, JUN 8, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-therapeutics-clinical-trial-validates-targeting-lsd1-inhibition [SID1234615797]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The purpose of the EPI-PRIMED study was to investigate the safety of the combination, nab-paclitaxel and an irreversible LSD1 inhibitor, in patients with metastatic breast cancer (mBC). Women with inoperable or metastatic breast cancer from three Australian facilities: Canberra Region Cancer Centre, Southern Medical Day Care Centre and Liverpool Hospital participated in the study. The results of this trial have now been published in leading cancer journal Frontiers of Oncology.
CEO Jeremy Chrisp said the results of the clinical trial provide proof of concept for the company’s current drug development program for its first in class therapies to inhibit nuclear LSD1. In particular EpiAxis was pleased to note the biomarker results indicate that inhibition of LSD1 was associated with phenotypic change away from an aggressive phenotype in cancer cells.
"The publication of this study is the culmination of several years’ work and the results are important for both patients and the company, as we have demonstrated that nuclear inhibition of LSD1 is possible and results in cell reprogramming," Dr Chrisp said.
"This indicates that we are on the right track to progress our novel first in class candidates to a new clinical trial. We would like to thank the staff and patients of the three sites that participated, as well as EpiAxis Therapeutics founding scientist Professor Sudha Rao. We look forward to sharing the immune data from the study in the near future."
The findings of the EPI-PRIMED study give EpiAxis a solid foundation for its next clinical trial using its novel peptide inhibitors. The company is currently working with The Sage Group to raise US$12million to advance a candidate into an IND enabled program.
Dr Chrisp will be attending the BIO International Convention with The Sage Group from 13-16 June 2022 at San Diego Convention Center to facilitate discussions with interested parties.